Press release

dsm-firmenich Brings Elevated Science, Quality and Health Benefit-Driven Innovation to the CBD Industry Via New Strategic Partnership with Mile High Labs

Parsippany, NJ (USA), 15 Jun 2021 09:00 EST/15:00 CEST

Royal dsm-firmenich, a global science-based company active in Nutrition, Health and Sustainable Living, announces it has entered into a broad commercial partnership with industry-leading cannabinoid ingredients and finished products manufacturer, Mile High Labs (MHL). The partnership extends dsm-firmenich’s capabilities as an innovative, end-to-end partner in nutrition and health — creating a platform from which leading consumer products companies can deliver novel, health-benefit driven products with globally trusted ingredients (based on local regulatory clearance). The relationship will also see MHL and dsm-firmenich partner in the development of unique hemp-derived cannabinoid solutions.

The cannabinoid market is fast-growing and powered by strong consumer interest. With consumers increasingly turning to cannabidiol (CBD) to address top health concerns like stress, mood and sleep among others, CBD is set to disrupt the dietary supplement category. These market conditions present an opportunity for a platform that supports brands in achieving rapid, scalable CBD growth.

Enabled by MHL’s large-scale 400,000 sq ft of manufacturing facilities, the partnership will see dsm-firmenich apply its advanced scientific, applications and formulations expertise to combine CBD and hemp derivatives with high-quality micronutrients. The resulting market-ready and premix solutions will enable dietary supplement, food and beverage and other nutritional product brands to deliver science-backed innovation with speed and confidence.

“There is a strong consumer pull in the CBD space for high-quality, health-benefit driven solutions, but as yet the market is still to arrive at recognized science or quality standards. dsm-firmenich has the core competencies, combined with a deep understanding of consumer and customer needs, to help brands enter the cannabinoid market early and build a leading position. Our science-backed solutions will deliver the purity, reliability and traceability that are currently lacking and enable our customers to truly differentiate themselves,” comments Frederic Boned, Vice President, Human Nutrition & Health at dsm-firmenich North America. “MHL is the ideal partner due to its staunch commitment to sustainability, quality and regulatory compliance, as well as its extensive cannabinoid manufacturing capabilities. Together, we are committed to developing the standards the cannabinoid industry sorely needs. Our complementary areas of expertise will support customers along the entire product development process.”

“MHL is excited to team up with such a credible player in human nutrition and health, and one that so closely aligns with our ambitions to uncover the full potential of this space,” adds Jonathan Hilley, Chief Executive Officer at MHL. “This partnership is an important milestone in the evolution of MHL and a defining moment for our industry. We look forward to pooling our expertise to deliver cannabinoid innovation that is scalable, sustainable, cost-effective and provides the building blocks for exciting new consumer products.”

dsm-firmenich’s move into the cannabinoid market once again highlights its position at the forefront of innovation in health through nutrition. dsm-firmenich’s longer-term ambitions leverage the company’s clinical, regulatory and applications expertise to explore the potential benefits of minor cannabinoids, and will see dsm-firmenich partner closely with customers to develop the next generations of science-backed cannabinoid solutions.

“This is just the beginning for dsm-firmenich. Our partnership with MHL will be a key enabler for us as we take our first steps in this burgeoning market,” dsm-firmenich’s Boned continues. “The potential of CBD and other hemp-derived cannabinoids hasn’t yet been fully realized, so we’re investing in the future of the category. As regulatory frameworks are defined, dsm-firmenich’s end-to-end capabilities and unrivalled portfolio make us ideally positioned to lead and shape the market. This category is full of promise, and we’re excited to partner with MHL and play an integral role in tapping into the potential and enabling customers to create products with real purpose. Watch this space!”

For more information, or to find out how dsm-firmenich and MHL can help you get to market faster with purpose-led CBD market-ready solutions, visit

For more information

Jennifer Himmelhoch

dsm-firmenich North America

Megan Cutts

Barrett Dixon Bell
+44 161 925 4700